Patents by Inventor John Kink

John Kink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrophage Cell Therapy to Treat Orthopedic Injury
    Publication number: 20240009233
    Abstract: An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 11, 2024
    Inventors: Peiman Hematti, Connie Chamberlain, Anna Elizabeth Breiner Clements, Ray Vanderby, John A. Kink
  • GENERATION OF THERAPEUTIC CELLS USING EXTRACELLULAR COMPONENTS OF TARGET ORGANS
    Publication number: 20230407256
    Abstract: The invention relates to an ex vivo generated population of tissue-specific anti-inflammatory macrophages and methods of making and using such macrophages.
    Type: Application
    Filed: August 17, 2023
    Publication date: December 21, 2023
    Inventors: Peiman Hematti, Eric G. Schmuck, John A. Kink, Amish N. Raval
  • Generation of therapeutic cells using extracellular components of target organs
    Patent number: 11760975
    Abstract: The invention relates to an ex vivo generated population of tissue-specific anti-inflammatory macrophages and methods of making and using such macrophages.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 19, 2023
    Assignee: Wisconsin Alumi Research Foundation
    Inventors: Peiman Hematti, Eric G. Schmuck, John A. Kink, Amish N. Raval
  • Macrophage cell therapy to treat orthopedic injury
    Patent number: 11738046
    Abstract: An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 29, 2023
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Peiman Hematti, Connie Chamberlain, Anna Elizabeth Breiner Clements, Ray Vanderby, John A. Kink
  • LPS priming of stromal cells to generate LPS-specific exosome educated macrophages
    Patent number: 11499730
    Abstract: The disclosure relates to an ex vivo generated population of educated macrophages specific to LPS and methods of making and using such macrophages.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: November 15, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Peiman Hematti, John A. Kink, Christian Capitini
  • LPS Priming of Stromal Cells to Generate LPS-Specific Exosome Educated Macrophages
    Publication number: 20220349599
    Abstract: The disclosure relates to an ex vivo generated population of educated macrophages specific to LPS and methods of making and using such macrophages.
    Type: Application
    Filed: July 12, 2022
    Publication date: November 3, 2022
    Inventors: Peiman Hematti, John A. Kink, Christian Capitini
  • Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury
    Publication number: 20220127579
    Abstract: The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkylglucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX.
    Type: Application
    Filed: October 22, 2021
    Publication date: April 28, 2022
    Inventors: Peiman HEMATTI, John KINK, Christian CAPITINI, Matthew FORSBERG, Nicholas HESS, Zachary ROSENKRANS, Reinier HERNANDEZ
  • LPS PRIMING OF STROMAL CELLS TO GENERATE LPS-SPECIFIC EXOSOME EDUCATED MACROPHAGES
    Publication number: 20190249144
    Abstract: The disclosure relates to an ex vivo generated population of educated macrophages specific to LPS and methods of making and using such macrophages.
    Type: Application
    Filed: February 12, 2019
    Publication date: August 15, 2019
    Inventors: Peiman Hematti, John A. Kink
  • MACROPHAGE CELL THERAPY TO TREAT ORTHOPEDIC INJURY
    Publication number: 20190134090
    Abstract: An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.
    Type: Application
    Filed: November 2, 2018
    Publication date: May 9, 2019
    Inventors: Peiman Hematti, Connie Chamberlain, Anna Elizabeth Breiner Clements, Ray Vanderby, John A. Kink
  • GENERATION OF THERAPEUTIC CELLS USING EXTRACELLULAR COMPONENTS OF TARGET ORGANS
    Publication number: 20180282698
    Abstract: The invention relates to an ex vivo generated population of tissue-specific anti-inflammatory macrophages and methods of making and using such macrophages.
    Type: Application
    Filed: March 30, 2018
    Publication date: October 4, 2018
    Inventors: Peiman Hematti, Eric G. Schmuck, John A. Kink, Amish N. Raval
  • Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
    Patent number: 9839638
    Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: December 12, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
  • Therapeutic ribonucleases
    Patent number: 9579365
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 28, 2017
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Methods and compositions for the treatment of cancer
    Patent number: 9192656
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 24, 2015
    Assignee: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: John A Kink, Laura E. Strong, Mark N. Shahan
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20150238575
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Application
    Filed: April 27, 2015
    Publication date: August 27, 2015
    Inventors: John A. Kink, Laura E. Strong, Mark N. Shahan
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20150209415
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: April 14, 2015
    Publication date: July 30, 2015
    Inventors: Tony Klink, John Kink, Laura Strong
  • Therapeutic ribonucleases
    Patent number: 9006407
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 14, 2015
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Modified ribonucleases
    Patent number: 8840882
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: September 23, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: John A. Kink, Laura E. Strong, Vladimir Trubetskoy, Mark N. Shahan
  • COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
    Publication number: 20140141060
    Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.
    Type: Application
    Filed: January 16, 2013
    Publication date: May 22, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20140128457
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 8, 2014
    Applicant: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Compositions and methods for ribonuclease-based therapeutics
    Patent number: 8697062
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: April 15, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Ronald T. Raines, Thomas J. Rutkoski, John A. Kink, Laura E. Strong